Other Information.
−Removed: During the three months ended March 31, 2026 , no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
−Removed: First Amendment to Context License Agreement
−Removed: On May 14, 2026, we entered into the Amendment to the Context License Agreement with Context.
−Removed: Under the terms of the Amendment, and in full consideration for the amended license rights described below, Context has agreed to pay us:
−Removed: (i) $4,500,000, payable within five (5) business days of the effective date of the Amendment, and (ii) $2,000,000, payable by August 1, 2026 (together, the "Amendment Pay-Off Amounts").
−Removed: The Amendment Pay-Off Amounts satisfy in full any and all milestone and royalty payment obligations contemplated by the Context License Agreement.
−Removed: Among other modifications to the Context License Agreement, under the terms of the Amendment, the license granted to Context under the Context License Agreement is amended to be irrevocable, exclusive, royalty-free, fully paid-up and non-terminable, and any and all diligence obligations with respect to Context are removed.
−Removed: The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment filed as Exhibit 10.3 to this Quarterly Report on Form 10-K and incorporated herein by reference.
+Added: During the three months ended June 30, 2026 , no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
+Added: First Amendment to EXUMA License Agreement
+Added: On August 12, 2026 (the “Effective Date”), we entered into the First Amendment (the “First Amendment”) to the Amended and Restated Exclusive License Agreement, dated November 22, 2019 (the “EXUMA License Agreement”), with EXUMA Biotech Corp.
+Added: (formerly F1 Oncology, Inc.), a Delaware corporation (“EXUMA”), covering certain CAR-T therapies.
+Added: Under the terms of the First Amendment, and in full consideration for the license and other rights granted by the Company under the EXUMA License Agreement, EXUMA has agreed to pay us $250,000 in immediately available funds within two (2) business days of the Effective Date (the “Amendment Pay-Off Amount”).
+Added: The Amendment Pay-Off Amount satisfies in full any and all royalty payment obligations contemplated by the EXUMA License Agreement.
+Added: Under the terms of the First Amendment, the exclusive license granted to EXUMA under the EXUMA License Agreement is amended to be royalty-free, fully paid-up, irrevocable, perpetual and non-terminable, and EXUMA shall be responsible for all Joint Patent (as defined in the EXUMA License Agreement) costs, whether currently outstanding or due in the future.
+Added: The above description of the First Amendment is qualified in its entirety by reference to the full text of the First Amendment, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2026.
Exhibit Filing Date
File/Furnished Herewith
−Removed: Agreement and Plan of Merger, dated as of January 30, 2026, by and between BioAtla, Inc.
−Removed: and Merger Sub.
−Removed: Form of Retention Bonus Agreement between BioAtla, Inc.
−Removed: and certain executive officers .
−Removed: Retention Bonus Agreement between BioAtla, Inc.
−Removed: and Jay Short, effective March 20, 2026
First Amendment to the License Agreement between BioAtla, Inc.
8 unchanged sentences
Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.
−Removed: The following materials from BioAtla’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, formatted in iXBRL (inline eXtensible Business Reporting Language):
−Removed: (i) the Condensed Balance Sheets, (ii) the Condensed Statements of Operations and Comprehensive Loss, (iii) the Condensed Statements of Stockholders’ Equity (iv) the Condensed Statements of Cash Flows, and (v) Notes to Condensed Financial Statements, tagged as blocks of text and including detailed tags.
+Added: The following materials from BioAtla’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, formatted in iXBRL (inline eXtensible Business Reporting Language):
+Added: (i) the Condensed Balance Sheets, (ii) the Condensed Statements of Operations and Comprehensive Income (Loss), (iii) the Condensed Statements of Stockholders’ Equity (Deficit), (iv) the Condensed Statements of Cash Flows, and (v) Notes to Condensed Financial Statements, tagged as blocks of text and including detailed tags.
Cover Page Interactive Data File (formatted as Inline XBRL document and contained in exhibit 101).
Furnished and not filed.
−Removed: + Indicates management contract or compensatory plan.
* Portions of this exhibit have been omitted or redacted in accordance with Item 601(a)(5) or Item 601(b)(10)(iv) of Regulation S-K.
1 unchanged sentence
BioAtla, Inc.
+Added: August 13, 2026
Chief Executive Officer
(Principal Executive Officer)
+Added: August 13, 2026
/s/ Christian Vasquez
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.